MOUNTAIN VIEW, Calif., March 29, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 10th Annual Needham Healthcare Conference.
The VIVUS presentation will take place at the Palace Hotel in New York, New York on Tuesday, April 5, 2011 at 2:00 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.
About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com. CONTACT: VIVUS, Inc.Investor Relations: The Trout GroupTimothy E. Morris
Brian KorbChief Financial Officer
|SOURCE VIVUS, Inc.|
Copyright©2010 PR Newswire.
All rights reserved